Turbine

Turbine operates the vLab, a virtual lab in which scientists run in silico experiments using Virtual Assays built on a Virtual Cell model. The platform predicts lab-like outputs, from cellular phenotypes to molecular states, across many biological conditions in parallel. A lab-in-the-loop workflow passes the most promising predictions to wet-lab validation, and the results feed back into later predictions.

The website describes its customers as biopharma companies and presents discovery and translational research as the main use cases. It names a discovery collaboration with Daiichi Sankyo on ADC discovery and includes endorsements from executives at Ono Pharmaceutical, MSD Global Health Fund and Accenture Ventures. The site invites visitors to book a demo and does not publish pricing or describe its revenue model in detail.

The company's leadership page lists Szabolcs Nagy (Co-Founder, CEO), Kristof Szalay (Founder, CTO) and Daniel Veres (Co-Founder, CSO). Its board includes investor directors from Series A and Series B rounds, and it lists a Series B observer from Merck. The website does not state a founding year or headquarters. Its open roles include a VP of AI Engine based in London and Cambridge, England.

Product: vLab, a virtual lab platform with Virtual Assays and a Virtual Cell model for running in silico biological experiments before wet-lab validation.